Literature DB >> 6401309

Inhibition of mitogen-induced proliferation of mouse T and B lymphocytes by bloodstream forms of Trypanosoma cruzi.

J R Maleckar, F Kierszenbaum.   

Abstract

The role of virulent forms of Trypanosoma cruzi in modulating mitogen-induced lymphocyte responses was investigated in this work. Bloodstream forms of T. cruzi inhibited normal mouse spleen cell responses to Con A and LPS in a dose-dependent manner. Reduced responses were observed over relatively large ranges of concentration of Con A (50-fold) and LPS (160-fold). The inhibitory action of the parasites could not be overcome by increasing the mitogen dose beyond optimal levels. Furthermore, absorption of mitogen solutions with four times as many parasites as used in the proliferation assays revealed that sufficient mitogen activity remained to produce optimal lymphocyte responses. Therefore, reduced lymphocyte responsiveness was not due to absorption of mitogen by the parasite. Inhibited responses were also seen when a sonicated T. cruzi preparation was used, indicating that parasite viability was not required to produce suppression. Inhibition of Con A- or LPS-induced responses by the parasites occurred only when the trypanosomes were incorporated into the system during the first 24 hr of culture. These results show that virulent forms of T. cruzi can induce suppression of T and B cell responses in vitro, and suggest that the parasite affects lymphocyte commitment to blastogenesis during the early stages of lymphocyte activation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401309

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  In vitro simulation of immunosuppression caused by Trypanosoma brucei.

Authors:  M Sileghem; A Darji; P De Baetselier
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

2.  Alterations in production of immunoglobulin classes and subclasses during experimental Trypanosoma cruzi infection.

Authors:  G K Jeng; F Kierszenbaum
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

3.  Suppression of human lymphocyte responses by Trypanosoma cruzi.

Authors:  L A Beltz; F Kierszenbaum
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

4.  Trypanosoma cruzi immunosuppressive factor decreases the interleukin-2 mRNA level in cultured normal activated human lymphocytes.

Authors:  S Majumder; F Kierszenbaum
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

5.  Selective suppressive effects of Trypanosoma cruzi on activated human lymphocytes.

Authors:  L A Beltz; F Kierszenbaum; M B Sztein
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

6.  Immunosuppressive effects of Centipeda periodontii: selective cytotoxicity for lymphocytes and monocytes.

Authors:  B J Shenker; P Berthold; P Dougherty; K K Porter
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

7.  Effects of extracts of Trypanosoma cruzi on immune responses: induction of a nonspecific suppressor factor.

Authors:  R L Tarleton; R Schafer; R E Kuhn
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

8.  Impairment in natural killer cells editing of immature dendritic cells by infection with a virulent Trypanosoma cruzi population.

Authors:  Estela I Batalla; Agustina M Pino Martínez; Carolina V Poncini; Tomás Duffy; Alejandro G Schijman; Stella M González Cappa; Catalina D Alba Soto
Journal:  J Innate Immun       Date:  2013-05-08       Impact factor: 7.349

9.  Suppression by Trypanosoma cruzi of T-cell receptor expression by activated human lymphocytes.

Authors:  M B Sztein; F Kierszenbaum
Journal:  Immunology       Date:  1992-10       Impact factor: 7.397

10.  Effect of the parasite enzyme, hypodermin A, on bovine lymphocyte proliferation and interleukin-2 production via the prostaglandin pathway.

Authors:  I Nicolas-Gaulard; N Moire; C Boulard
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.